Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A11664 | ISIN: US03209R1032 | Ticker-Symbol: 29A
Tradegate
28.03.24
15:16 Uhr
41,600 Euro
+0,800
+1,96 %
1-Jahres-Chart
AMPHASTAR PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
AMPHASTAR PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
40,20041,20028.03.
40,40041,00028.03.

Aktuelle News zur AMPHASTAR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.03.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference373RANCHO CUCAMONGA, CA / ACCESSWIRE / March 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations...
► Artikel lesen
05.03.Amphastar a new overweight at J.P. Morgan on diverse asset portfolio7
02.03.Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2023 Earnings Call Transcript2
01.03.Earnings call: Amphastar Pharmaceuticals sees revenue jump in 20234
01.03.Amphastar Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary6
29.02.Amphastar Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
28.02.Amphastar Pharmaceuticals, Inc. - 8-K, Current Report7
28.02.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023291Reports Net Revenues of $178.1 Million for the Three Months Ended December 31, 2023RANCHO CUCAMONGA, CA / ACCESSWIRE / February 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar"...
► Artikel lesen
27.02.Earnings Outlook For Amphastar Pharma5
21.02.Amphastar (AMPH) to Report Q4 Earnings: What's in the Cards?2
20.02.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024355RANCHO CUCAMONGA, CA / ACCESSWIRE / February 20, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2023 ended December 31...
► Artikel lesen
16.02.It May Be Time To Revisit Amphastar Once It Settles After A Plunge4
02.01.Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference502RANCHO CUCAMONGA, CA / ACCESSWIRE / January 2, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Dr. Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at...
► Artikel lesen
20.11.23Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference365RANCHO CUCAMONGA, CA / ACCESSWIRE / November 20, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, S.V.P. of Corporate Communications, will...
► Artikel lesen
17.11.23BofA starts Amphastar at neutral; cites high valuation, Baqsimi prospects11
15.11.23Amphastar Pharmaceuticals director discloses sale of 5K shares3
10.11.23Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade6
09.11.23Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference438RANCHO CUCAMONGA, CA / ACCESSWIRE / November 9, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi EVP of Corp. Administration, will participate...
► Artikel lesen
09.11.23Amphastar Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary6
08.11.23Amphastar Pharmaceuticals, Inc. - 10-Q, Quarterly Report3
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2